Tscan Therapeutics Stock Current Liabilities
| TCRX Stock | USD 4.52 0.26 6.10% |
Tscan Therapeutics fundamentals help investors to digest information that contributes to Tscan Therapeutics' financial success or failures. It also enables traders to predict the movement of Tscan Stock. The fundamental analysis module provides a way to measure Tscan Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tscan Therapeutics stock.
Total Current Liabilities is likely to drop to about 19.4 M in 2024. Non Current Liabilities Total is likely to drop to about 70.1 M in 2024. Tscan | Current Liabilities |
Tscan Therapeutics Company Current Liabilities Analysis
Tscan Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Tscan Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Tscan Therapeutics is extremely important. It helps to project a fair market value of Tscan Stock properly, considering its historical fundamentals such as Current Liabilities. Since Tscan Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tscan Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tscan Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Tscan Current Liabilities Historical Pattern
Today, most investors in Tscan Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tscan Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Tscan Therapeutics current liabilities as a starting point in their analysis.
Tscan Therapeutics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Tscan Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Tscan Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Tscan Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tscan Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics of similar companies.Tscan Therapeutics is currently under evaluation in current liabilities category among its peers.
Tscan Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tscan Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tscan Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Tscan Fundamentals
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (31.10) % | ||||
| Current Valuation | 46.59 M | ||||
| Shares Outstanding | 49.09 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 93.37 % | ||||
| Number Of Shares Shorted | 2.16 M | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 0.99 X | ||||
| Price To Sales | 24.29 X | ||||
| Revenue | 21.05 M | ||||
| Gross Profit | (46.28 M) | ||||
| EBITDA | (80.1 M) | ||||
| Net Income | (89.22 M) | ||||
| Cash And Equivalents | 125.6 M | ||||
| Cash Per Share | 5.22 X | ||||
| Total Debt | 92.43 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 4.29 X | ||||
| Cash Flow From Operations | (61.36 M) | ||||
| Short Ratio | 11.66 X | ||||
| Earnings Per Share | (0.95) X | ||||
| Target Price | 12.57 | ||||
| Number Of Employees | 188 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 227.36 M | ||||
| Total Asset | 272.15 M | ||||
| Retained Earnings | (247.6 M) | ||||
| Working Capital | 164.42 M | ||||
| Net Asset | 272.15 M |
About Tscan Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tscan Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.